Navidea To Initiate Regular Webcast Series Featuring Moderated Q&A with Management
August 30 2017 - 5:18PM
Business Wire
First Webcast Scheduled with CFO for Tuesday,
September 5, 2017 at 4:30pm ET
Navidea Biopharmaceuticals (NYSE MKT: NAVB) (Navidea or The
Company), a company focused on the development of precision
immunodiagnostic agents and through its subsidiary Macrophage
Therapeutics, immunotherapeutics, announced today that it will hold
an Investor Relations (IR)-focused, online Question & Answer
(Q&A) Session with Jed Latkin, Chief Financial and Chief
Operating Officer of Navidea on Tuesday, September 5 at 4:30pm
Eastern Time. Investors are invited to submit questions they would
like to hear answered to ir@navidea.com or tpatel@edisongroup.com
by Monday, September 4, 2017.
From time to time, between quarterly conference calls, the
management will host Q&A webcasts so investors and potential
investors can learn more about the Company, its strategy, and its
products.
Event:
Navidea IR Q&A Session – September 2017
Date:
Tuesday, September 5, 2017
Time:
4:30pm ET
Webcast:
http://www.audio-webcast.com/cgi-bin/visitors.ssp?fn=visitor&id=4973
Navidea management plans to host Q&A sessions every other
month, beginning with the first session on September 5, to field
common or important questions its shareholders and potential
investors have. This ongoing Q&A series will bring the Company
ever closer to its shareholder base and is designed to maintain a
continued open forum to highlight the Company’s clinical trial
progress as well as the many milestones Navidea hopes to achieve
over the next several quarters.
For the September 5 IR-focused Q&A Session, Navidea invites
all interested investors to submit questions they would like to see
asked by Monday, September 4, 2017 to ir@navidea.com or
tpatel@edisongroup.com.
“Navidea is committed to driving shareholder value and we
recognize that to succeed in the highly competitive pharmaceutical
industry one must provide cutting edge technology and products.
This requires focus and the ability to attract and retain world
class scientists and innovators. The process is time consuming and
never proceeds in a straight line and to insure existing and
potential investors in the company have an opportunity to gain
greater clarity on the prospects for Navidea we are initiating this
effort. We anticipate that this format will prove useful to
investors and productive for our small management team,” commented
Michael Goldberg, M.D., President and Chief Executive Officer of
Navidea.
About Navidea Biopharmaceuticals
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a
biopharmaceutical company focused on the development of precision
immunodiagnostic agents and immunotherapeutics. Navidea is
developing multiple precision-targeted products based on its
Manocept™ platform to enhance patient care by identifying the sites
and pathways of disease and enable better diagnostic accuracy,
clinical decision-making, and targeted treatment. Navidea’s
Manocept platform is predicated on the ability to specifically
target the CD206 mannose receptor expressed on activated
macrophages. The Manocept platform serves as the molecular backbone
of Tc 99m tilmanocept, the first product developed and
commercialized by Navidea based on the platform. The development
activities of the Manocept immunotherapeutic platform are being
conducted by Navidea in conjunction with its subsidiary, Macrophage
Therapeutics, Inc. Navidea’s strategy is to deliver superior growth
and shareholder return by bringing to market novel products and
advancing the Company’s pipeline through global partnering and
commercialization efforts.
For more information, please visit http://www.navidea.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170830006261/en/
Navidea BiopharmaceuticalsJed Latkin, CFO/COO,
614-973-7490jlatkin@navidea.comorEdison AdvisorsTirth Patel,
646-653-7035tpatel@edisongroup.com
Navidea Biopharmaceuticals (AMEX:NAVB)
Historical Stock Chart
From Aug 2024 to Sep 2024
Navidea Biopharmaceuticals (AMEX:NAVB)
Historical Stock Chart
From Sep 2023 to Sep 2024